Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
12/17/18 12:20 AM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Dec 3 2018
Summary ToggleAdverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
- Dec 3 2018
Summary ToggleAdverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
- Nov 19 2018
Summary ToggleAdverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
- Nov 13 2018
Summary ToggleAdverum to Present at 30th Annual Piper Jaffray Healthcare Conference
There are currently no events to display.